G

GSK

Develops medicines, vaccines, and consumer health

People Services Operations Specialist - With German

Full-TimeUpdated
PLN84k - PLN140k/yr+ Annual bonus + Share-based long-term incentive program
Mid
Poznań, Poland
HybridHybrid work from Poznan.
People & HRHR Operations & Coordination

About the job

Requirements
  • Fluent German and English language skills, both written and spoken.
  • Experience in HR Operations, HR Administration, Shared Services, People Services, Payroll Administration, Time & Attendance, or a related field.
  • Experience managing employee lifecycle transactions and HR data within HR systems.
  • Strong attention to detail with a demonstrated commitment to accuracy and quality.
  • Ability to manage multiple priorities and work effectively in a fast-paced environment.
  • Strong customer service and stakeholder communication skills.
  • Ability to work confidently with confidential employee information.
  • Proficiency with Microsoft Office applications, particularly Excel.
  • Willingness to work in a hybrid model from Poznan.
Responsibilities
  • Deliver end-to-end HR administration support across the employee lifecycle, including hiring, contractual changes, leave management, and offboarding activities.
  • Process HR transactions accurately and within agreed service levels while ensuring compliance with company policies and local German regulations.
  • Prepare and maintain employee documentation and HR records in accordance with legal and regulatory requirements.
  • Execute payroll-impacting transactions accurately and on time, recognizing the critical impact of HR data quality on employee pay.
  • Act as a primary point of contact for employees, managers, and HR stakeholders through case management and digital support channels.
  • Provide guidance on routine HR policies, processes, and lifecycle transactions.
  • Resolve inquiries efficiently while delivering a high-quality customer experience.
  • Partner closely with HR Business Partners, Centres of Excellence, Payroll teams, and other stakeholders to ensure seamless service delivery.
  • Maintain accurate employee data within HR systems, ensuring completeness, consistency, and compliance.
  • Identify and resolve data discrepancies and proactively support data quality initiatives.
  • Utilize HR systems such as Workday, SAP, and ServiceNow to manage transactions and employee records.
  • Support reporting activities and contribute to data-driven decision making through accurate system management.
  • Support payroll processes through timely and accurate execution of payroll-relevant transactions.
  • Perform validations, audits, and controls to ensure payroll-impacting data is correct before payroll processing.
  • Collaborate with payroll teams and vendors to investigate and resolve data-related issues.
  • Identify opportunities to simplify, improve, and standardize HR processes.
  • Participate in process improvement projects, knowledge transfers, and operational excellence initiatives.
  • Contribute ideas that improve efficiency, quality, employee experience, and service delivery performance.
  • Support the team's journey toward greater standardization, digitalization, and automation.
  • Handle sensitive personal and employment data with the highest level of confidentiality.
  • Ensure compliance with data privacy requirements, local legislation, internal controls, and company policies.
  • Follow established governance, documentation, and process standards.
Desired Qualifications
  • Experience supporting employees within the German market.
  • Knowledge of German HR administration and payroll processes.
  • Previous experience in a Shared Services, Global Business Services, or HR Operations environment.
  • Experience with Workday, ServiceNow, and/or SAP HR.
  • Exposure to process improvement, standardization, Lean, Continuous Improvement, or automation initiatives.
  • Experience working with payroll vendors or payroll-impacting HR processes.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.

Yahoo Finance
Oct 25th, 2026
HUTCHMED licenses HMPL-A830 to GSK in a deal worth up to $1.3B, with $110M upfront

HUTCHMED (China) has closed an exclusive licence agreement giving a GSK subsidiary rights to develop and commercialise HMPL-A830 worldwide, outside Mainland China, Hong Kong, Macau, and Taiwan. HUTCHMED receives $110 million upfront, plus up to $1.185 billion in potential milestones and tiered royalties. The GSK subsidiary will bear later-stage development and commercialisation costs. HUTCHMED keeps global Phase I responsibility and Greater China rights. The deal partly diversifies a business that still relies on a few oncology drugs, such as fruquintinib and savolitinib, and on China sales.

Yahoo Finance
Oct 24th, 2026
GSK's $2.2B Zantac charge tests whether specialty medicines can carry Q3 results

GSK reports third-quarter results on October 28, with a $2.2 billion Zantac settlement charge weighing on the numbers. Consensus expects earnings per share to fall 9% year on year to $1.33, while revenue is forecast at $8.81 billion against $8.55 billion a year ago. The settlement resolves 93% of outstanding US state court cases. Investors will watch how management separates the charge from core results. Specialty Medicines grew 14% last quarter. Long-acting HIV injectables Cabenuva and Apretude rose 33% and 39%, driving 80% of ViiV's growth. The key launch to track is Exdensur, whose J-code went live on July 1. More than 50% of insured patients now have coverage, so new patient starts will be the key metric.

Pharmaceutical Executive
Oct 23rd, 2026
CSL names Deborah Waterhouse as CEO and manager director.

CSL names Deborah Waterhouse as CEO and manager director. Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL. ViiV Healthcare has announced that Deborah Waterhouse is stepping down as chief executive officer of ViiV Healthcare and president of GSK Global Health to join CSL as chief executive officer and managing director. Lynn Baxter, currently president of GSK Europe, is set to be appointed chief executive officer of ViiV Healthcare and president of GSK Global Health, effective November 1, 2026.[1] Waterhouse's move to CSL is set to take effect February 1, 2027, following an extensive global search conducted by CSL's board. What does this mean for ViiV and CSL? Waterhouse has led ViiV Healthcare since 2017, with the company reporting sales of $10.2 billion during GSK's 2025 financial year.[1] She also served as president of GSK Global Health, a role she will relinquish alongside the ViiV CEO post. Baxter was previously leading ViiV's U.S. business for six years before moving into her current GSK Europe role, and will now oversee both ViiV Healthcare and GSK Global Health.[1] Waterhouse is expected to work with Baxter on a transition at ViiV before departing. At CSL, Gordon Naylor will continue serving as interim CEO and managing director until Waterhouse's February 2027 start date, after which he will return to the CSL board as a non-executive director.[1,2] Waterhouse will retain her base in the U.K. while spending significant time in Australia, the U.S., and CSL's other major markets and operational centers.[1,2] What is Waterhouse's track record? Waterhouse brings more than 25 years of experience managing complex global specialty pharma businesses across the U.S., U.K., continental Europe, and Australia. Before ViiV, she was the leader of GSK's U.S. vaccines business and its U.S. primary care business, along with serving as GSK's general manager for Australia and New Zealand between 2008 and 2012.[1] CSL frames her ViiV tenure as evidence she can deliver the combination of commercial growth and pipeline renewal the company says it is seeking in its next chapter. GSK leadership credits Waterhouse's tenure with both commercial and mission-driven results. "During her tenure as CEO, ViiV advanced important innovations in HIV treatment and prevention, expanded patient access to medicines, delivered sustained business growth, and strengthened its long-term strategic position," says David Redfern, chairman of the ViiV board and president of corporate development at GSK. On Baxter's appointment, he adds that her "deep experience across the biopharmaceutical industry, proven commercial leadership, and longstanding commitment to patients position her well to lead ViiV Healthcare through its next phase of growth." CSL chair Brian McNamee points to specific capabilities behind the board's decision. "She has grown a focused biopharmaceutical business and renewed the franchise at ViiV by driving the development and commercialization of the next generation of medicines to support patients," he says. "She knows the United States, she knows Australia and she knows how to build pipelines and manage partnerships." McNamee said the board's decision to appoint Waterhouse was unanimous.[2] Waterhouse addressed both moves directly. On her ViiV exit: "It has been a privilege to lead ViiV Healthcare and GSK Global Health and work alongside so many talented colleagues, partners, and advocates." She then touched on joining CSL, saying, "The foundations are strong. My job is to continue the momentum and evolve the path into reliable growth for patients and shareholders. ViiV Healthcare has reshaped the treatment and prevention landscape for people impacted by HIV. I am honored to take on this role and look forward to working with colleagues around the world to continue advancing innovation."

Yahoo Finance
Oct 23rd, 2026
GSK shares up 20.4% despite 5.2% net margin as $10.6B Nuvalent deal lifts pipeline hopes

GSK shares have risen 20.4% over the past year, including dividends, even as the company's profitability weakened. The stock now trades at £19.14, up from £16.52 at the start of the period. Revenue reached £8,409m, but net income slipped to £435m and net margin fell to 5.2%. GSK agreed to buy Nuvalent for $10.6 billion to deepen its lung cancer pipeline. It also won approvals for Jideytro, Hibsago, and the new antibiotic Utebzi. The bullish case puts fair value at £23.63, assuming 8.5% annual revenue growth and margins rising to 19.8% by 2028. The bearish case puts it at £11.2, citing cost pressure, HIV patent expiries, and pricing and legal risks. GSK plans to fund growth through a £1.9 billion cost-saving programme and site closures.